AustraliaHealth

AFT Pharmaceuticals (ASX:AFP) recorded sustained double-digit sales growth across its entire global portfolio for the March quarter of 2026.

Paradigm Biopharmaceuticals (ASX:PAR) announced a strategic research collaboration with City St George's, University of London.

Vitura Health (ASX:VIT) announced the appointment of Justin James as its new CEO.

Emyria (ASX:EMD) has launched a targeted clinical workforce recruitment campaign in New South Wales.

Pathkey.AI (ASX:PKY) has executed a strategic services agreement with Imunexus Therapeutics.

Healthscope remains current with its financial obligations, having paid 100% of all rent due across its hospital portfolio up to and including April..

Bioxyne (ASX:BXN) announced a strategic manufacturing agreement with the Canadian-based industry giant, Aurora Cannabis.

Lumos Diagnostics (ASX:LDX) announced its largest purchase order to date for its flagship FebriDx rapid point-of-care test.

Neurizon Therapeutics (ASX:NUZ) has unveiled compelling new preclinical data regarding its lead compound, NUZ-001.

Biopharmaceutical innovator Firebrick Pharma (ASX:FRE) has secured $1.5 million in firm commitments through a strategic placement.

Paradigm Biopharmaceuticals (ASX:PAR) confirmed that 50% of the required participants have now been dosed in its PARA_OA_012 Phase 3 clinical trial.

Alterity Therapeutics (ASX:ATH) announced alignment with the US Food and Drug Administration following a pivotal Type C meeting.